Joseph Kovalchin
Overview
Explore the profile of Joseph Kovalchin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
56
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pinkstaff J, McCullagh E, Grover A, Melton A, Cherukuri A, Wait J, et al.
Toxicol Rep
. 2023 Mar;
10:357-366.
PMID: 36923444
Mucopolysaccharidosis Type IIIB (MPS IIIB) is an ultrarare, fatal pediatric disease with no approved therapy. It is caused by mutations in the gene encoding for lysosomal enzyme alpha-N-acetylglucosaminidase (NAGLU). Tralesinidase...
2.
Muschol N, Koehn A, von Cossel K, Okur I, Ezgu F, Harmatz P, et al.
J Clin Invest
. 2022 Nov;
133(2).
PMID: 36413418
BackgroundSanfilippo type B is a mucopolysaccharidosis (MPS) with a major neuronopathic component characterized by heparan sulfate (HS) accumulation due to mutations in the NAGLU gene encoding alfa-N-acetyl-glucosaminidase. Enzyme replacement therapy...
3.
Ellinwood N, Valentine B, Hess A, Jens J, Snella E, Jamil M, et al.
J Pharmacol Exp Ther
. 2022 Jun;
382(3):277-286.
PMID: 35717448
Mucopolysaccharidosis type IIIB (MPS IIIB; Sanfilippo syndrome B; OMIM #252920) is a lethal, pediatric, neuropathic, autosomal recessive, and lysosomal storage disease with no approved therapy. Patients are deficient in the...
4.
Okur I, Ezgu F, Giugliani R, Muschol N, Koehn A, Amartino H, et al.
J Pediatr
. 2022 Jun;
249:50-58.e2.
PMID: 35709957
Objective: To characterize the longitudinal natural history of disease progression in pediatric subjects affected with mucopolysaccharidosis (MPS) IIIB. Study Design: Sixty-five children with a confirmed diagnosis of MPS IIIB were...
5.
Rubio-Beltran E, Labastida-Ramirez A, Haanes K, van den Bogaerdt A, Bogers A, Zanelli E, et al.
Br J Pharmacol
. 2019 Aug;
176(24):4681-4695.
PMID: 31418454
Background And Purpose: Triptans are 5-HT receptor agonists (that also display 5-HT receptor affinity) with antimigraine action, contraindicated in patients with coronary artery disease due to their vasoconstrictor properties. Conversely,...
6.
Kovalchin J, King B, Masci A, Hopkins E, Fry J, Hou J, et al.
Eye Contact Lens
. 2017 Jul;
44(3):170-181.
PMID: 28727604
Objective: Topical interleukin (IL)-1 receptor (R)1 blockade is therapeutically active in reducing signs and symptoms of dry eye disease. Herein, we describe in vitro and in vivo nonclinical Investigational New...
7.
Goldstein M, Tubridy K, Agahigian J, Furfine E, Magill M, Kovalchin J, et al.
Eye Contact Lens
. 2015 Apr;
41(3):145-55.
PMID: 25915834
Objectives: Many allergic conjunctivitis (AC) patients are inadequately treated with conventional therapies or require steroids. EBI-005 was developed to address the late phase allergic response. This study's objectives were to...
8.
Kovalchin J, Krieger J, Genova M, Kawamoto N, Augustyniak M, Collins K, et al.
PLoS One
. 2011 Dec;
6(12):e26274.
PMID: 22194778
The random amino acid copolymer poly(Y,E,A,K)(n) (Copaxone®) is widely used in multiple sclerosis treatment and a second generation copolymer poly(Y,F,A,K)(n) with enhanced efficacy in experimental autoimmune encephalomyelitis in mice has...
9.
Kovalchin J, Krieger J, Collins K, Genova M, Augustyniak M, Masci A, et al.
J Clin Pharmacol
. 2010 Oct;
51(5):649-60.
PMID: 20940336
PI-2301 is an amino acid copolymer acting as an immunomodulator for the treatment of autoimmune diseases. The present study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics of PI-2301 in a...